WHO Functional Class IV Portopulmonary Hypertension When Triple Therapy Did Not Achieve Hemodynamic Targets

This protocol addresses the next step for patients with WHO functional class IV portopulmonary hypertension — or pulmonary hypertension not meeting low-risk criteria — after triple combination therapy has failed to achieve the required hemodynamic response on follow-up evaluation.

Clinical Scenario

Prostacyclin agonists are reserved for patients with WHO functional class IV or for any patient with pulmonary hypertension not meeting low-risk criteria. This high-severity subpopulation requires close hemodynamic monitoring and structured protocol-driven escalation when initial targets are not met.

Previous Treatment — Targets Not Achieved

The prior line consisted of triple therapy: a prostacyclin agonist combined with an endothelin receptor antagonist and a phosphodiesterase 5 inhibitor.

Mean pulmonary arterial pressure below 35 mm Hg and pulmonary vascular resistance below 3 WU — required on 3-month follow-up heart catheterization — were not achieved.
Next-Step Approach

For patients who have not met hemodynamic targets on triple therapy, guideline-recommended management considers orthotopic liver transplantation — with eligibility determined by specific hemodynamic criteria defined in the full protocol.

Instant Access to Structured Evidence-Based Regimens
References
DOI: 10.1097/TXD.0000000000001517 View source ↗